The Global Ventricular Tachycardia Market is estimated to be valued at USD 15.52 Bn in 2025 and is expected to reach USD 22.28 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 5.3% from ...

Despite HCM’s strong genetic basis, patients residing in lower-income or more socially deprived areas faced significantly ...

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

The clinic will be able to accommodate 1,500 patients over a long period and 50 patients with a left ventricular assist ...

Patients with pre-existing high blood pressure are more likely to be susceptible to heart damage caused by anthracyclines, the most widely used chemotherapy drugs for cancer treatment for more than 30 ...

This article originally appeared in the National Association of EMS Physicians blog and is reprinted here with permission. By ...

Higher baseline serum magnesium levels are linked to a higher risk for cardiac events in HFmrEF/HFpEF, while empagliflozin treatment shows a lower risk for these events in those with higher magnesium.

Morgans Scott Power positive of renewed momentum in the healthcare sector, which has risen 0.7% in the week ending January 16 ...

Longer times from symptom onset to randomization equaled a smaller—or perhaps no—advantage for Impella vs standard care.

Events picked up with the Fourth Universal Definition of MI were tied to higher mortality, emphasizing the role of ancillary ...

Cardamyst FDA approval and launch for PSVT, solid cash, and big expansion upside. Click for more on MIST stock.

As many as 189 health conditions could potentially affect your legal ability to drive. Both physical and mental health ...